The Effects of the CF Carrier State on the Kidneys and Pancreas

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorPhilip Polgreen

About this trial

The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.

Eligibility criteria

Qualifiers

A CF Carrier identified via genetic testing

No previous CF carrier test results

Disqualifiers

CF patient status

Unable to speak English

Currently pregnant

Unable to provide written informed consent

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,250 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Philip Polgreen

Lead sponsor

University of Iowa

Sponsor institution

National Institutes of Health (NIH)

Collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator